CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.
Overview
Investing in biotechnology requires a balance between groundbreaking scientific innovation and the realities of clinical development. Choosing between CRISPR Therapeutics (NASDAQ:CRSP) and Viking Therapeutics (NASDAQ:VKTX) involves comparing established gene-editing leadership against massive growth potential in metabolic medicine.
CRISPR Therapeutics is a leader in gene editing, recently achieving its first product approval for rare blood disorders. Viking Therapeutics focuses on metabolic and endocrine disorders, targeting the booming market for weight-loss treatments. While both companies operate in high-growth areas, their financial stages and clinical risks offer distinct paths for everyday investors.
Details
CRISPR Therapeutics focuses on developing gene-based medicines using its proprietary CRISPR/Cas9 platform. The company develops gene-based medicines, a transformative part of healthcare stocks. It currently relies on a strategic partnership with Vertex Pharmaceuticals (NASDAQ:VRTX) for the commercialization of CASGEVY, a treatment for sickle cell disease. Customer concentration like this adds a layer of risk to the business since one partner controls most global operations.
Source
Originally published at www.fool.com.